JP4790984B2 - アルファウイルスレプリコンベクター系 - Google Patents
アルファウイルスレプリコンベクター系 Download PDFInfo
- Publication number
- JP4790984B2 JP4790984B2 JP2003527091A JP2003527091A JP4790984B2 JP 4790984 B2 JP4790984 B2 JP 4790984B2 JP 2003527091 A JP2003527091 A JP 2003527091A JP 2003527091 A JP2003527091 A JP 2003527091A JP 4790984 B2 JP4790984 B2 JP 4790984B2
- Authority
- JP
- Japan
- Prior art keywords
- alphavirus
- rna
- structural protein
- helper
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000710929 Alphavirus Species 0.000 title claims abstract description 315
- 239000013598 vector Substances 0.000 title description 61
- 239000002245 particle Substances 0.000 claims abstract description 82
- 230000010076 replication Effects 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 51
- 208000015181 infectious disease Diseases 0.000 claims abstract description 29
- 230000002458 infectious effect Effects 0.000 claims abstract description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 223
- 101710172711 Structural protein Proteins 0.000 claims description 145
- 210000004027 cell Anatomy 0.000 claims description 127
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 106
- 108020004414 DNA Proteins 0.000 claims description 100
- 238000004520 electroporation Methods 0.000 claims description 38
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 37
- 238000004806 packaging method and process Methods 0.000 claims description 36
- 108020004511 Recombinant DNA Proteins 0.000 claims description 31
- 230000035772 mutation Effects 0.000 claims description 26
- 230000006798 recombination Effects 0.000 claims description 26
- 238000005215 recombination Methods 0.000 claims description 26
- 238000013518 transcription Methods 0.000 claims description 26
- 230000035897 transcription Effects 0.000 claims description 26
- 108091026890 Coding region Proteins 0.000 claims description 24
- 239000013612 plasmid Substances 0.000 claims description 24
- 230000002238 attenuated effect Effects 0.000 claims description 23
- 102000053602 DNA Human genes 0.000 claims description 21
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 13
- 108010087302 Viral Structural Proteins Proteins 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 11
- 230000002950 deficient Effects 0.000 claims description 10
- 101710132906 Structural polyprotein Proteins 0.000 claims description 8
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims description 7
- 241000710942 Ross River virus Species 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 4
- 230000010474 transient expression Effects 0.000 claims 5
- 230000001052 transient effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 abstract description 123
- 102000039446 nucleic acids Human genes 0.000 abstract description 29
- 108020004707 nucleic acids Proteins 0.000 abstract description 29
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 241001068263 Replication competent viruses Species 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 93
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 93
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 93
- 108090000623 proteins and genes Proteins 0.000 description 81
- 210000000234 capsid Anatomy 0.000 description 79
- 108090000994 Catalytic RNA Proteins 0.000 description 62
- 102000053642 Catalytic RNA Human genes 0.000 description 62
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 62
- 108091092562 ribozyme Proteins 0.000 description 62
- 241000700605 Viruses Species 0.000 description 46
- 108091005804 Peptidases Proteins 0.000 description 45
- 239000004365 Protease Substances 0.000 description 45
- 108090000288 Glycoproteins Proteins 0.000 description 38
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 38
- 235000019419 proteases Nutrition 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 37
- 102000003886 Glycoproteins Human genes 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 32
- 108091008146 restriction endonucleases Proteins 0.000 description 31
- 239000012634 fragment Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 101150084101 RNA2 gene Proteins 0.000 description 18
- 101100353432 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRP2 gene Proteins 0.000 description 18
- 241000710188 Encephalomyocarditis virus Species 0.000 description 17
- 238000003776 cleavage reaction Methods 0.000 description 17
- 238000010276 construction Methods 0.000 description 17
- 230000007017 scission Effects 0.000 description 17
- 210000003501 vero cell Anatomy 0.000 description 17
- 108090000565 Capsid Proteins Proteins 0.000 description 15
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 15
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 15
- 239000005090 green fluorescent protein Substances 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 13
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 13
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 12
- 102100023321 Ceruloplasmin Human genes 0.000 description 12
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 12
- 241000723754 Flock house virus Species 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 101150023114 RNA1 gene Proteins 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 241000724709 Hepatitis delta virus Species 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 108020003589 5' Untranslated Regions Proteins 0.000 description 8
- 208000037262 Hepatitis delta Diseases 0.000 description 8
- 108091092724 Noncoding DNA Proteins 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 208000029570 hepatitis D virus infection Diseases 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 101710127721 Membrane protein Proteins 0.000 description 7
- 101800000514 Non-structural protein 4 Proteins 0.000 description 7
- 108700002693 Viral Replicase Complex Proteins Proteins 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108010076039 Polyproteins Proteins 0.000 description 6
- 108010009460 RNA Polymerase II Proteins 0.000 description 6
- 102000009572 RNA Polymerase II Human genes 0.000 description 6
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 108091023045 Untranslated Region Proteins 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 101800000515 Non-structural protein 3 Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 101800000980 Protease nsP2 Proteins 0.000 description 4
- 241000251131 Sphyrna Species 0.000 description 4
- 101710137500 T7 RNA polymerase Proteins 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000021251 pulses Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 101800001631 3C-like serine proteinase Proteins 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101710091919 Eukaryotic translation initiation factor 4G Proteins 0.000 description 3
- 101710177291 Gag polyprotein Proteins 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 101800004803 Papain-like protease Proteins 0.000 description 3
- 101800002227 Papain-like protease nsp3 Proteins 0.000 description 3
- 101800001074 Papain-like proteinase Proteins 0.000 description 3
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 3
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 241000710960 Sindbis virus Species 0.000 description 3
- 108010076818 TEV protease Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000009585 enzyme analysis Methods 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004779 membrane envelope Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000723733 Boolarra virus Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 101150117028 GP gene Proteins 0.000 description 2
- 108091027874 Group I catalytic intron Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 101100264173 Homo sapiens XIAP gene Proteins 0.000 description 2
- 101800000120 Host translation inhibitor nsp1 Proteins 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 101800000512 Non-structural protein 1 Proteins 0.000 description 2
- 101800000511 Non-structural protein 2 Proteins 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 241000710078 Potyvirus Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108090000621 Ribonuclease P Proteins 0.000 description 2
- 102000004167 Ribonuclease P Human genes 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 241000723838 Turnip mosaic virus Species 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 2
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- -1 aliphatic amino acid Chemical class 0.000 description 2
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 2
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000028499 poly(A) binding Human genes 0.000 description 2
- 108091023021 poly(A) binding Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 1
- 241000317943 Acute bee paralysis virus Species 0.000 description 1
- 241000253994 Acyrthosiphon pisum Species 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 241000178568 Aura virus Species 0.000 description 1
- 241000724681 Barley yellow mosaic virus Species 0.000 description 1
- 241000710073 Bean yellow mosaic virus Species 0.000 description 1
- 241000318498 Black queen cell virus Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 241000231316 Buggy Creek virus Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000710127 Cricket paralysis virus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000010567 DNA Polymerase II Human genes 0.000 description 1
- 108010063113 DNA Polymerase II Proteins 0.000 description 1
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 1
- 101000678286 Danio rerio Eukaryotic translation initiation factor 4E-binding protein 3-like Proteins 0.000 description 1
- 101000800913 Dictyostelium discoideum Eukaryotic translation initiation factor 4E-1A-binding protein homolog Proteins 0.000 description 1
- 241000907524 Drosophila C virus Species 0.000 description 1
- 101000800906 Drosophila melanogaster Eukaryotic translation initiation factor 4E-binding protein Proteins 0.000 description 1
- 101100232687 Drosophila melanogaster eIF4A gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150082674 E2 gene Proteins 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102100039737 Eukaryotic translation initiation factor 4 gamma 2 Human genes 0.000 description 1
- 241000465885 Everglades virus Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000231322 Fort Morgan virus Species 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108091029499 Group II intron Proteins 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 1
- 241000710948 Highlands J virus Species 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101001034811 Homo sapiens Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 241000231318 Kyzylagach virus Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000608292 Mayaro virus Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 241000608287 Ndumu virus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000723741 Nodaviridae Species 0.000 description 1
- 101710152005 Non-structural polyprotein Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical class 0.000 description 1
- 241000723992 Ornithogalum mosaic virus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000723990 Papaya ringspot virus Species 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 241000723784 Plum pox virus Species 0.000 description 1
- 101710114167 Polyprotein P1234 Proteins 0.000 description 1
- 101710124590 Polyprotein nsP1234 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 241001455595 Sorghum mosaic virus Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000044038 Tenebroides mauritanicus Species 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 241000723790 Tobacco vein mottling virus Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000608278 Una virus Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067674 Viral Nonstructural Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 241000710951 Western equine encephalitis virus Species 0.000 description 1
- 241000132050 Yam mosaic virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011259 co-electroporation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000004265 eukaryotic small ribosome subunit Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108010028403 hemagglutinin esterase Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
- C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
- C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Memory System Of A Hierarchy Structure (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31772201P | 2001-09-06 | 2001-09-06 | |
| US60/317,722 | 2001-09-06 | ||
| PCT/US2002/028610 WO2003023026A1 (en) | 2001-09-06 | 2002-09-06 | Alphavirus replicon vector systems |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005508159A JP2005508159A (ja) | 2005-03-31 |
| JP2005508159A5 JP2005508159A5 (enExample) | 2011-01-20 |
| JP4790984B2 true JP4790984B2 (ja) | 2011-10-12 |
Family
ID=23234980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003527091A Expired - Lifetime JP4790984B2 (ja) | 2001-09-06 | 2002-09-06 | アルファウイルスレプリコンベクター系 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7045335B2 (enExample) |
| EP (1) | EP1432791B2 (enExample) |
| JP (1) | JP4790984B2 (enExample) |
| AT (1) | ATE437222T1 (enExample) |
| AU (1) | AU2002327614B2 (enExample) |
| CA (1) | CA2460269C (enExample) |
| DE (1) | DE60233061D1 (enExample) |
| ES (1) | ES2330202T5 (enExample) |
| WO (1) | WO2003023026A1 (enExample) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| GB0019745D0 (en) * | 2000-08-10 | 2000-09-27 | Univ Surrey | Gene expression element |
| US7045335B2 (en) | 2001-09-06 | 2006-05-16 | Alphavax, Inc. | Alphavirus replicon vector systems |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| EP2360169B1 (en) | 2001-10-23 | 2015-10-14 | Psma Development Company, L.L.C. | PSMA antibodies |
| JP5079981B2 (ja) | 2002-12-13 | 2012-11-21 | アルファバックス，インコーポレイティド | アルファウイルス粒子及び調製方法 |
| EP1585812B1 (en) | 2002-12-13 | 2017-01-18 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
| KR101518309B1 (ko) * | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
| EP1651666B1 (en) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| US20050257277A1 (en) * | 2004-05-17 | 2005-11-17 | Xiaobin Lu | Regulation of transcription with a cis-acting ribozyme |
| ES2321212T3 (es) * | 2004-05-18 | 2009-06-03 | Alphavax, Inc. | Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion. |
| ES2647491T3 (es) | 2004-05-21 | 2017-12-21 | Novartis Vaccines And Diagnostics, Inc. | Vectores del alfavirus para las vacunas del virus de la gripe |
| WO2006076032A2 (en) * | 2004-05-25 | 2006-07-20 | Novartis Vaccines And Diagnostics Inc. | Alphavirus replicon packaging constructs |
| US7862829B2 (en) * | 2004-07-09 | 2011-01-04 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| US7332322B2 (en) * | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| US7998733B2 (en) * | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
| WO2007046839A2 (en) * | 2005-02-15 | 2007-04-26 | University Of North Carolina At Chapel Hill | New live virus vaccines |
| US20100247565A1 (en) * | 2005-06-29 | 2010-09-30 | Ilya Frolov | Chimeric sindbis-eastern equine encephalitis virus and uses thereof |
| AU2007342333B2 (en) | 2006-09-12 | 2013-02-28 | Alphavax, Inc. | Alphavirus replicon particles encoding IL- 12 as immunological adjuvants |
| ES2517869T3 (es) | 2006-09-12 | 2014-11-04 | Alphavax, Inc. | Partículas de replicones de alfavirus emparejadas con antígenos proteicos como adyuvantes inmunológicos |
| CA2668417A1 (en) * | 2006-11-03 | 2008-05-15 | Alphavax, Inc. | Alphavirus and alphavirus replicon particle formulations and methods |
| ES2517615T3 (es) * | 2006-11-09 | 2014-11-03 | The United States Of America As Represented By The Secretary Of The Navy | Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo |
| US8748591B2 (en) * | 2007-04-17 | 2014-06-10 | The Board Of Regents Of The University Of Texas System | Chimeric sindbis-western equine encephalitis virus and uses thereof |
| DK2183368T3 (en) | 2007-06-21 | 2016-09-05 | Alphavax Inc | PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS |
| EP2205751A2 (en) * | 2007-09-26 | 2010-07-14 | Vanderbilt University | Vaccine for rsv and mpv |
| US20100040650A1 (en) * | 2008-05-30 | 2010-02-18 | Crowe Jr James E | Virus-Like paramyxovirus particles and vaccines |
| WO2009156155A1 (en) * | 2008-06-25 | 2009-12-30 | Probiogen Ag | Cell line for propagation of highly attenuated alphaviruses |
| US9296790B2 (en) | 2008-10-03 | 2016-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for protein delivery |
| US8680258B2 (en) * | 2008-12-01 | 2014-03-25 | Alphavax, Inc. | Use of microRNAs to control virus helper nucleic acids |
| US20120128714A1 (en) | 2009-04-08 | 2012-05-24 | Wolchok Jedd D | Alphavirus Replicon Particles Expressing TRP2 |
| WO2011130125A1 (en) * | 2010-04-12 | 2011-10-20 | Viracine Therapeutics Corporation | Expression of positive sense single stranded rna virus and uses thereof |
| US11291635B2 (en) * | 2010-07-06 | 2022-04-05 | Glaxosmithkline Biological Sa | Virion-like delivery particles for self-replicating RNA molecules |
| SI2591114T1 (sl) | 2010-07-06 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Imunizacija velikih sesalcev z majhnimi odmerki RNA |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| WO2012031043A1 (en) * | 2010-08-31 | 2012-03-08 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| BR112013004879A2 (pt) * | 2010-08-31 | 2018-04-24 | Novartis Ag | lipossomas pequenos para entrega de rna que codifica imunogénio |
| EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
| US10004797B2 (en) | 2010-10-27 | 2018-06-26 | Harrisvaccines, Inc. | Method of rapidly producing improved vaccines for animals |
| US8822427B2 (en) | 2010-10-27 | 2014-09-02 | Harrisvaccines | Methods and compositions to protect aquatic invertebrates from disease |
| WO2012058072A1 (en) | 2010-10-27 | 2012-05-03 | Harrisvaccines, Inc | Method of rapidly producing vaccines for animals |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| EP4014966A1 (en) | 2011-07-06 | 2022-06-22 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| WO2013066665A1 (en) | 2011-10-19 | 2013-05-10 | Harrisvaccines, Inc | Method of rapidly producing improved vaccines for animals |
| CA2860310C (en) | 2011-12-21 | 2023-03-21 | Apse, Llc | Processes using vlps with capsids resistant to hydrolases |
| EP3663395B1 (en) | 2012-03-26 | 2024-07-31 | The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology, Transfer, | Delivery of packaged rna to mammalian cells |
| CA2873964C (en) | 2012-05-21 | 2025-09-16 | The Regents Of The University Of California | GENERATION OF HUMAN IP CELLS BY SELF-REPLICATING SYNTHETIC RNA |
| BR112015029559A2 (pt) | 2013-06-19 | 2017-12-12 | Apse Llc | partícula similar a vírus, ácido nucleico e métodos para produzir rna de fita dupla e sirna, shrna, sshrna, 1shrna e mirna |
| TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| KR102467982B1 (ko) | 2013-12-16 | 2022-11-16 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법 |
| WO2016037164A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
| WO2017162265A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| WO2018129268A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
| BR112019019813A2 (pt) | 2017-03-30 | 2020-04-22 | The University Of Queensland | moléculas quiméricas e usos das mesmas |
| EP3687561A4 (en) | 2017-09-01 | 2021-06-09 | The Australian National University | "immunoregulatory molecules and uses therefor" |
| MX2020003838A (es) | 2017-10-13 | 2020-08-06 | Selecta Biosciences Inc | Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral. |
| BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
| SG11202005792RA (en) | 2017-12-20 | 2020-07-29 | Vlp Therapeutics Llc | Alphavirus replicon particle |
| KR20200139679A (ko) | 2018-02-26 | 2020-12-14 | 안톨알엑스, 인크. | 면역관용성 리포솜 및 그의 사용 방법 |
| WO2020028749A1 (en) * | 2018-08-03 | 2020-02-06 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
| BR112021021566A2 (pt) | 2019-04-28 | 2022-04-19 | Selecta Biosciences Inc | Métodos para tratamento de indivíduos com imunidade preexistente a vetores de transferência viral |
| BR112021023594A2 (pt) | 2019-05-28 | 2022-02-08 | Selecta Biosciences Inc | Métodos e composições para resposta imune de vetor de transferência antiviral atenuada |
| US20220396806A1 (en) | 2019-07-26 | 2022-12-15 | Akouos, Inc. | Methods of treating hearing loss using a secreted target protein |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| US11730799B2 (en) * | 2019-10-18 | 2023-08-22 | University Of Iowa Research Foundation | Cancer vaccines and methods of producing and using same |
| MX2022007905A (es) | 2019-12-31 | 2022-08-25 | Elixirgen Therapeutics Inc | Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos. |
| CA3171231A1 (en) | 2020-03-09 | 2021-09-16 | Sean Michael Sullivan | Compositions and methods for inducing immune responses |
| JP2023518976A (ja) | 2020-03-23 | 2023-05-09 | エイチディーティー バイオ コーポレーション | Ｒｎａを送達するための組成物および方法 |
| EP4135847A4 (en) | 2020-04-17 | 2024-05-15 | VLP Therapeutics, Inc. | Coronavirus vaccine |
| WO2021221127A1 (en) | 2020-04-30 | 2021-11-04 | Vlp Therapeutics, Inc. | Cytokine immunotherapy |
| EP4165194A2 (en) | 2020-05-13 | 2023-04-19 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
| AR122078A1 (es) | 2020-05-13 | 2022-08-10 | Akouos Inc | Composiciones y métodos para tratar la pérdida auditiva asociada a slc26a4 |
| CN116171150A (zh) | 2020-08-14 | 2023-05-26 | 阿克丘勒斯治疗公司 | 冻干脂质纳米颗粒的方法 |
| WO2022087006A1 (en) * | 2020-10-20 | 2022-04-28 | George Mason Research Foundation, Inc. | Hybrid alphavirus-sars-cov-2 particle and methodology of making and using same |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| KR20230127263A (ko) | 2020-12-29 | 2023-08-31 | 아카우오스, 인크. | Clrn1-연관된 청력손실 및/또는 시력손실을 치료하기위한 조성물 및 방법 |
| JP2024535354A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | がん治療組成物およびその使用 |
| KR20240096468A (ko) | 2021-09-22 | 2024-06-26 | 에이치디티 바이오 코포레이션 | 감염병에 대한 rna 백신 |
| AU2022349251A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Sars-cov-2 rna vaccine compositions and methods of use |
| KR20240088845A (ko) | 2021-09-22 | 2024-06-20 | 에이치디티 바이오 코포레이션 | 건조된 나노입자 조성물 |
| AU2022356427A1 (en) | 2021-09-30 | 2024-05-09 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| EP4473011A1 (en) | 2022-02-02 | 2024-12-11 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| US12084703B2 (en) | 2022-05-12 | 2024-09-10 | SunVax mRNA Therapeutics Inc. | Synthetic self-amplifying mRNA molecules with secretion antigen and immunomodulator |
| TW202408545A (zh) | 2022-07-08 | 2024-03-01 | 美國貝勒醫學院 | 整合的壓力反應抑制劑及其使用方法 |
| WO2024126423A1 (en) | 2022-12-12 | 2024-06-20 | Precision NanoSystems ULC | Lipid nanoparticles lyophilization methods and compositions |
| AU2024266138A1 (en) | 2023-05-03 | 2025-11-13 | Manifold Biotechnologies, Inc. | Methods and compositions for high-throughput protein delivery, screening, and detection |
| EP4474015A1 (en) | 2023-06-05 | 2024-12-11 | Veterna Srl | Noda-like rna-vaccine pharmacon and production and uses thereof |
| WO2025242657A1 (en) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Lipopeptide building blocks and aggregates |
| CN120555458A (zh) * | 2025-05-29 | 2025-08-29 | 杭州依思康医药科技有限公司 | 一种猫疱疹病毒rna疫苗及其在猫科动物鼻气管炎中的应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11504802A (ja) * | 1994-11-30 | 1999-05-11 | カイロン コーポレイション | 組換えアルファウイルスベクター |
| JPH11505719A (ja) * | 1995-05-23 | 1999-05-25 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | アルファウイルスｒｎａレプリコン系 |
| WO1999050432A1 (en) * | 1998-03-27 | 1999-10-07 | Cytos Biotechnology Ag | Inducible alphaviral gene expression system |
| WO2000039318A1 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| JP2005515755A (ja) * | 2001-05-31 | 2005-06-02 | カイロン コーポレイション | キメラアルファウイルスレプリコン粒子 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) * | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4650764A (en) * | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US5091309A (en) * | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| NZ225583A (en) * | 1987-08-06 | 1991-07-26 | Merck & Co Inc | Process for purifying hepatitis a virions (hav) |
| US5217879A (en) * | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5185440A (en) * | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| US6770283B1 (en) * | 1990-12-13 | 2004-08-03 | Bioption Ab | DNA expression systems based on alphaviruses |
| SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
| US20020102273A1 (en) * | 1995-08-08 | 2002-08-01 | Robert B. Grieve | Use of alphavirus expression vectors to produce parasite anitgens |
| AU6172194A (en) * | 1993-02-08 | 1994-08-29 | Paravax, Inc. | Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens |
| RU2057377C1 (ru) | 1993-08-23 | 1996-03-27 | Уральский электрохимический комбинат | Способ переработки оружейного высокообогащенного урана и его сплавов в топливный материал для атомных реакторов |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| EP0711829A3 (en) | 1993-09-15 | 1997-07-09 | Viagene Inc | Recombinant alphavirus vector |
| SE9401091D0 (sv) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
| SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US5505947A (en) * | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5703057A (en) * | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US5639650A (en) | 1995-05-23 | 1997-06-17 | The University Of North Carolina At Chapel Hill | cDNA clone for South African Arbovirus No. 86 |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| WO1997040165A1 (en) * | 1996-04-23 | 1997-10-30 | The Wistar Institute Of Anatomy And Biology | Novel human cytomegalovirus dna constructs and uses therefor |
| US5853719A (en) * | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| CZ438398A3 (cs) * | 1996-07-01 | 1999-03-17 | Rhone-Poulenc Rorer S. A. | Způsob přípravy rekombinantních adenovirů |
| JP2965908B2 (ja) | 1996-07-05 | 1999-10-18 | 株式会社精工技研 | 調温液体シール手段を備える光ディスク成形用金型装置 |
| US5827658A (en) * | 1996-08-09 | 1998-10-27 | The United States Of America As Reprsented By The Department Of Health And Human Services | Isolation of amplified genes via cDNA subtractive hybridization |
| US5726022A (en) * | 1996-11-18 | 1998-03-10 | Lifespan Biosciences, Inc. | Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences |
| WO1998022588A2 (en) * | 1996-11-20 | 1998-05-28 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US5811407A (en) * | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
| US5958738A (en) * | 1997-03-24 | 1999-09-28 | Roche Diagnostics Corporation | Procedure for subtractive hybridization and difference analysis |
| US6261570B1 (en) * | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
| GB9716611D0 (en) | 1997-08-07 | 1997-10-08 | Cantab Pharmaceuticals Res Ltd | Virus preparations and methods |
| AUPO856097A0 (en) | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
| US6197502B1 (en) * | 1997-11-17 | 2001-03-06 | Cytos Biotechnology Ag | Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property |
| GB9804632D0 (en) * | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| US6844188B1 (en) * | 1998-04-08 | 2005-01-18 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
| AU754320B2 (en) | 1998-04-08 | 2002-11-14 | University Of North Carolina At Chapel Hill, The | Methods and modified cells for the treatment of cancer |
| EP1080218A1 (en) * | 1998-05-27 | 2001-03-07 | University of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient |
| WO2000000616A2 (en) * | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
| US6770479B1 (en) * | 1998-07-10 | 2004-08-03 | The United States Of America As Represented By The Secretary Of The Army | Anthrax vaccine |
| ATE382693T1 (de) * | 1998-07-10 | 2008-01-15 | U S Army Medical Res Inst Of I | Impfstoffe gegen neurotoxine von clostridium botulinum |
| DE69940157D1 (en) * | 1998-07-10 | 2009-02-05 | U S Medical Res Inst Of Infect | Anthrax-impfstoff |
| AU6289699A (en) * | 1998-10-05 | 2000-04-26 | Genzyme Corporation | Genes differentially expressed in cancer cells to design cancer vaccines |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| US6329201B1 (en) * | 1998-12-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| EP1980617A1 (en) | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| DK1175497T3 (da) | 1999-04-14 | 2010-05-31 | Novartis Vaccines & Diagnostic | Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer |
| US6495743B1 (en) * | 1999-06-28 | 2002-12-17 | University Of Hawaii | Plant xylanases |
| AU782645B2 (en) | 1999-08-31 | 2005-08-18 | University Of North Carolina At Chapel Hill, The | Antibody dependent enhancement (ADE) of alphavirus infection |
| AU2001275191A1 (en) * | 2000-05-31 | 2001-12-11 | Chiron Corporation | Method for the purification of alphavirus replicon particles |
| WO2002003917A2 (en) | 2000-07-07 | 2002-01-17 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified hiv genes for use as vaccines |
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| JP3544925B2 (ja) * | 2000-07-27 | 2004-07-21 | 株式会社東芝 | 番組予約機能を備えた放送受信システムとその放送受信装置及び番組予約端末 |
| DE60103902T2 (de) | 2000-07-28 | 2005-06-30 | Visteon Global Technologies, Inc., Dearborn | Ansaugsystem für brennkraftmaschine |
| CN1250731C (zh) * | 2000-08-29 | 2006-04-12 | 惠氏控股公司 | 正链rna病毒复制子颗粒的包装 |
| US6982087B2 (en) * | 2000-09-07 | 2006-01-03 | The University Of North Carolina At Chapel Hill | Vectors derived from South African Arbovirus No. 86 |
| US6800289B2 (en) * | 2000-12-21 | 2004-10-05 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Strain of the western equine encephalitis virus |
| AU2002305914A1 (en) | 2001-01-12 | 2002-10-21 | Chiron Corporation | Nucleic acid mucosal immunization |
| US20030232324A1 (en) * | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
| US7045335B2 (en) | 2001-09-06 | 2006-05-16 | Alphavax, Inc. | Alphavirus replicon vector systems |
| WO2003083065A2 (en) | 2002-03-25 | 2003-10-09 | University Of North Carolina At Chapel Hill | Improved methods for achieving expression from alphavirus vectors |
| JP3857195B2 (ja) * | 2002-07-09 | 2006-12-13 | 株式会社東芝 | 距離継電装置 |
| US20050031592A1 (en) * | 2002-11-13 | 2005-02-10 | Doolan Denise L. | Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines |
| JP5079981B2 (ja) | 2002-12-13 | 2012-11-21 | アルファバックス，インコーポレイティド | アルファウイルス粒子及び調製方法 |
| EP1585812B1 (en) * | 2002-12-13 | 2017-01-18 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
| KR101518309B1 (ko) | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
| EP1651666B1 (en) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
-
2002
- 2002-09-06 US US10/237,302 patent/US7045335B2/en not_active Expired - Lifetime
- 2002-09-06 AU AU2002327614A patent/AU2002327614B2/en not_active Expired
- 2002-09-06 CA CA2460269A patent/CA2460269C/en not_active Expired - Lifetime
- 2002-09-06 ES ES02763613.3T patent/ES2330202T5/es not_active Expired - Lifetime
- 2002-09-06 AT AT02763613T patent/ATE437222T1/de not_active IP Right Cessation
- 2002-09-06 JP JP2003527091A patent/JP4790984B2/ja not_active Expired - Lifetime
- 2002-09-06 DE DE60233061T patent/DE60233061D1/de not_active Expired - Lifetime
- 2002-09-06 WO PCT/US2002/028610 patent/WO2003023026A1/en not_active Ceased
- 2002-09-06 EP EP02763613.3A patent/EP1432791B2/en not_active Expired - Lifetime
-
2006
- 2006-03-16 US US11/376,901 patent/US7425337B2/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11504802A (ja) * | 1994-11-30 | 1999-05-11 | カイロン コーポレイション | 組換えアルファウイルスベクター |
| JPH11505719A (ja) * | 1995-05-23 | 1999-05-25 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | アルファウイルスｒｎａレプリコン系 |
| WO1999050432A1 (en) * | 1998-03-27 | 1999-10-07 | Cytos Biotechnology Ag | Inducible alphaviral gene expression system |
| WO2000039318A1 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| JP2005515755A (ja) * | 2001-05-31 | 2005-06-02 | カイロン コーポレイション | キメラアルファウイルスレプリコン粒子 |
Also Published As
| Publication number | Publication date |
|---|---|
| US7425337B2 (en) | 2008-09-16 |
| US20030119182A1 (en) | 2003-06-26 |
| EP1432791B2 (en) | 2013-10-23 |
| ES2330202T3 (es) | 2009-12-07 |
| DE60233061D1 (de) | 2009-09-03 |
| ES2330202T5 (es) | 2014-01-20 |
| US7045335B2 (en) | 2006-05-16 |
| ATE437222T1 (de) | 2009-08-15 |
| EP1432791A4 (en) | 2005-07-27 |
| AU2002327614B2 (en) | 2007-12-06 |
| JP2005508159A (ja) | 2005-03-31 |
| CA2460269C (en) | 2013-01-15 |
| CA2460269A1 (en) | 2003-03-20 |
| EP1432791A1 (en) | 2004-06-30 |
| US20060177819A1 (en) | 2006-08-10 |
| WO2003023026A1 (en) | 2003-03-20 |
| EP1432791B1 (en) | 2009-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7425337B2 (en) | Alphavirus replicon vector systems | |
| AU2002327614A1 (en) | Alphavirus replicon vector systems | |
| US6329201B1 (en) | Compositions and methods for packaging of alphavirus vectors | |
| EP1141361B1 (en) | Compositions and methods for packaging of alphavirus vectors | |
| JP5268196B2 (ja) | キメラアルファウイルスレプリコン粒子 | |
| EP0694070B1 (en) | Recombinant alphavirus vectors | |
| EP0760000B1 (en) | Alphavirus expression vector | |
| CA2689588C (en) | Promoterless cassettes for expression of alphavirus structural proteins | |
| JP2005515755A5 (enExample) | ||
| CA2518546A1 (en) | Improved alphavirus replicons and helper constructs | |
| WO2008119827A1 (en) | Transreplicase constructs | |
| CA2407050A1 (en) | Alphavirus-based vectors for persistent infection | |
| Rausalu et al. | Properties and use of novel replication-competent vectors based on Semliki Forest virus | |
| EP1029069B9 (en) | Alphavirus vectors | |
| Lu et al. | Transmission of replication-defective Sindbis helper vectors encoding capsid and envelope proteins | |
| CA2719413A1 (en) | Compositions and methods for packaging of alphavirus vectors | |
| MXPA00004707A (es) | Vectores de alfa virus | |
| HK1155984A (en) | Chimeric alphavirus replicon particles | |
| HK1084692B (en) | Improved alphavirus replicons and helper constructs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050829 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081128 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090227 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090527 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100528 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100826 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100902 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20101129 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110701 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110721 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140729 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4790984 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |